These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

58 related items for PubMed ID: 10543144

  • 1. [Platinum derivatives].
    Sasaki Y.
    Nihon Rinsho; 1999 Sep; 57 Suppl():425-7. PubMed ID: 10543144
    [No Abstract] [Full Text] [Related]

  • 2. [Platinum derivatives].
    Sasaki Y.
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():452-5. PubMed ID: 15658361
    [No Abstract] [Full Text] [Related]

  • 3. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate.
    Brouwers EE, Tibben MM, Rosing H, Hillebrand MJ, Joerger M, Schellens JH, Beijnen JH.
    J Mass Spectrom; 2006 Sep; 41(9):1186-94. PubMed ID: 16929560
    [Abstract] [Full Text] [Related]

  • 4. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
    Jacobs SS, Fox E, Dennie C, Morgan LB, McCully CL, Balis FM.
    Clin Cancer Res; 2005 Feb 15; 11(4):1669-74. PubMed ID: 15746072
    [Abstract] [Full Text] [Related]

  • 5. The interaction of platinum-based drugs with native biologically relevant proteins.
    Brauckmann C, Wehe CA, Kieshauer M, Lanvers-Kaminsky C, Sperling M, Karst U.
    Anal Bioanal Chem; 2013 Feb 15; 405(6):1855-64. PubMed ID: 23052861
    [Abstract] [Full Text] [Related]

  • 6. [Pharmacokinetic properties of platinium derivatives].
    Boisdron-Celle M, Lebouil A, Allain P, Gamelin E.
    Bull Cancer; 2001 Aug 15; 88 Spec No():S14-9. PubMed ID: 11567909
    [Abstract] [Full Text] [Related]

  • 7. [Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA) in humans].
    Zucca E, Cattaneo MT, Cavalli F, Guaitani A, Filipazzi V, Bartosek I.
    G Ital Chemioter; 1985 Aug 15; 32(1):25-8. PubMed ID: 3913618
    [No Abstract] [Full Text] [Related]

  • 8. Comparative protein binding, stability and degradation of satraplatin, JM118 and cisplatin in human plasma in vitro.
    Bell DN, Liu JJ, Tingle MD, Rattel B, Meyer TU, McKeage MJ.
    Clin Exp Pharmacol Physiol; 2008 Dec 15; 35(12):1440-6. PubMed ID: 18671714
    [Abstract] [Full Text] [Related]

  • 9. Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates.
    Jacobs S, McCully CL, Murphy RF, Bacher J, Balis FM, Fox E.
    Cancer Chemother Pharmacol; 2010 Apr 15; 65(5):817-24. PubMed ID: 19662415
    [Abstract] [Full Text] [Related]

  • 10. A shotgun approach for the identification of platinum-protein complexes.
    Moraleja I, Moreno-Gordaliza E, Esteban-Fernández D, Mena ML, Linscheid MW, Gómez-Gómez MM.
    Anal Bioanal Chem; 2015 Mar 15; 407(9):2393-403. PubMed ID: 25618759
    [Abstract] [Full Text] [Related]

  • 11. Determination of platinum drug release and liposome stability in human plasma by CE-ICP-MS.
    Nguyen TT, Ostergaard J, Stürup S, Gammelgaard B.
    Int J Pharm; 2013 Jun 05; 449(1-2):95-102. PubMed ID: 23583709
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The kinetics and mechanisms of the reaction of Mesna with cisplatin, oxiplatin and carboplatin.
    Oprea A, Bazzazi H, Kangarloo B, Wolff JE.
    Anticancer Res; 2001 Jun 05; 21(2A):1225-9. PubMed ID: 11396168
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Quantification and clinical application of carboplatin in plasma ultrafiltrate.
    Downing K, Jensen BP, Grant S, Strother M, George P.
    J Pharm Biomed Anal; 2017 May 10; 138():373-377. PubMed ID: 28260690
    [Abstract] [Full Text] [Related]

  • 20. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
    Hanada K, Asano K, Nishimura T, Chimata T, Matsuo Y, Tsuchiya M, Ogata H.
    J Pharm Pharmacol; 2008 Mar 10; 60(3):317-22. PubMed ID: 18284811
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.